A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer

scientific article published in January 2004

A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1042528582
P356DOI10.1007/BF02968045
P698PubMed publication ID15604993

P2093author name stringMamoru Fukuda
Satoru Shimizu
Takashi Suda
Takashi Ishikawa
Yutaka Tokuda
Akira Ishiyama
Hiroshi Shimada
Eisuke Fukuma
Masaaki Inaba
Kazuo Ishida
Yohei Hamaguchi
Taro Asaga
Kanagawa Breast Cancer Treatment Society (KBCTS)
Kiyohumi Katayama
P2860cites workChemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensQ35976425
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerQ36134486
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of CancerQ36135843
P433issue4
P921main subjectdocetaxelQ420436
P304page(s)374-379
P577publication date2004-01-01
P1433published inBreast CancerQ15752871
P1476titleA multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer
P478volume11

Reverse relations

cites work (P2860)
Q37957744Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
Q33776899The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

Search more.